Wendy Halpern

2.6k total citations
42 papers, 1.5k citations indexed

About

Wendy Halpern is a scholar working on Immunology, Molecular Biology and Oncology. According to data from OpenAlex, Wendy Halpern has authored 42 papers receiving a total of 1.5k indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Immunology, 15 papers in Molecular Biology and 8 papers in Oncology. Recurrent topics in Wendy Halpern's work include Immunotoxicology and immune responses (8 papers), Animal testing and alternatives (7 papers) and Cell death mechanisms and regulation (6 papers). Wendy Halpern is often cited by papers focused on Immunotoxicology and immune responses (8 papers), Animal testing and alternatives (7 papers) and Cell death mechanisms and regulation (6 papers). Wendy Halpern collaborates with scholars based in United States, Switzerland and United Kingdom. Wendy Halpern's co-authors include A. Corey, Norma Lynn Fox, Robin Humphreys, Gilles Gallant, Theresa A. Mays, Kristin Padavic, Margaret von Mehren, Amita Patnaik, Roger B. Cohen and Anthony W. Tolcher and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Clinical Cancer Research.

In The Last Decade

Wendy Halpern

38 papers receiving 1.5k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Wendy Halpern United States	16	848	472	353	233	181	42	1.5k
Motohiro Kobayashi Japan	24	1.1k 1.3×	669 1.4×	435 1.2×	93 0.4×	131 0.7×	102	2.2k
Carme de Bolós Spain	29	1.3k 1.6×	621 1.3×	396 1.1×	227 1.0×	92 0.5×	54	2.2k
Shiro Ohshima Japan	23	809 1.0×	816 1.7×	519 1.5×	146 0.6×	189 1.0×	77	2.3k
Kisho Ono Japan	20	860 1.0×	166 0.4×	290 0.8×	75 0.3×	415 2.3×	89	1.5k
Kyung Un Choi South Korea	25	699 0.8×	273 0.6×	557 1.6×	96 0.4×	337 1.9×	148	2.2k
István Vályi‐Nagy Hungary	20	499 0.6×	201 0.4×	359 1.0×	57 0.2×	149 0.8×	90	1.4k
Alfredo Ribeiro‐Silva Brazil	26	658 0.8×	166 0.4×	890 2.5×	82 0.4×	444 2.5×	124	2.1k
Nicholas L. Kovach United States	20	735 0.9×	703 1.5×	167 0.5×	301 1.3×	293 1.6×	23	2.2k
Duane H. Hamilton United States	25	726 0.9×	876 1.9×	1.2k 3.4×	56 0.2×	335 1.9×	49	2.2k
Shyam S. Chauhan India	25	1.1k 1.3×	241 0.5×	609 1.7×	48 0.2×	671 3.7×	103	2.1k

Countries citing papers authored by Wendy Halpern

Since Specialization

Citations

This map shows the geographic impact of Wendy Halpern's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Wendy Halpern with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Wendy Halpern more than expected).

Fields of papers citing papers by Wendy Halpern

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Wendy Halpern. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Wendy Halpern. The network helps show where Wendy Halpern may publish in the future.

Co-authorship network of co-authors of Wendy Halpern

This figure shows the co-authorship network connecting the top 25 collaborators of Wendy Halpern. A scholar is included among the top collaborators of Wendy Halpern based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Wendy Halpern. Wendy Halpern is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Sutaria, Dhruvitkumar S., Rodney A. Prell, Wendy Halpern, et al.. (2025). Quantifying Risk of Delayed QT Prolongation of Ipatasertib in Preclinical and Clinical Studies in Cancer Patients. Clinical and Translational Science. 18(7). e70298–e70298. 1 indexed citations

Authier, Simon, Marcus S. Delatte, Wendy Halpern, et al.. (2025). Toxicology and safety pharmacology investigations on the nervous system: 2024 industry survey. Journal of Pharmacological and Toxicological Methods. 135. 108378–108378.

Chen, Connie L., Wendy Halpern, Bethany R. Hannas, et al.. (2024). HESI workshop summary: Interpretation of developmental and reproductive toxicity endpoints and the impact on data interpretation of adverse events. Birth Defects Research. 116(2). e2311–e2311. 1 indexed citations

Rao, Gautham K., et al.. (2023). Repeat-dose and embryo-fetal developmental toxicity of zinpentraxin alfa. Reproductive Toxicology. 123. 108526–108526. 1 indexed citations

Adedeji, Adeyemi O., et al.. (2022). Neutropenia in Cynomolgus Monkeys With Anti-Drug Antibodies Associated With Administration of Afucosylated Humanized Monoclonal Antibodies. Toxicologic Pathology. 50(8). 910–919. 1 indexed citations

Ackley, David H., Todd Bourcier, Andrew L. Goodwin, et al.. (2022). FDA and industry collaboration: Identifying opportunities to further reduce reliance on nonhuman primates for nonclinical safety evaluations. Regulatory Toxicology and Pharmacology. 138. 105327–105327. 22 indexed citations

Vidal, Justin D., Karyn Colman, Manoj Bhaskaran, et al.. (2021). Scientific and Regulatory Policy Committee Best Practices: Documentation of Sexual Maturity by Microscopic Evaluation in Nonclinical Safety Studies. Toxicologic Pathology. 49(5). 977–989. 5 indexed citations

Stagg, Nicola J., Paula Katavolos, Amrita V. Kamath, et al.. (2021). Nonclinical toxicology development of a novel antibody antibiotic conjugate for treating invasive Staphylococcus Aureus infections. Toxicology and Applied Pharmacology. 435. 115811–115811. 5 indexed citations

Rocca, Meredith S., LaRonda L. Morford, Diann Blanset, et al.. (2018). Applying a weight of evidence approach to the evaluation of developmental toxicity of biopharmaceuticals. Regulatory Toxicology and Pharmacology. 98. 69–79. 13 indexed citations

10.

Fisher, Jeffrey W., et al.. (2018). Physiology of the Neonatal Gastrointestinal System Relevant to the Disposition of Orally Administered Medications. Drug Metabolism and Disposition. 47(3). 296–313. 51 indexed citations

11.

Berridge, Brian R., Peter Hoffmann, James R. Turk, et al.. (2012). Integrated and translational nonclinical in vivo cardiovascular risk assessment: Gaps and opportunities. Regulatory Toxicology and Pharmacology. 65(1). 38–46. 12 indexed citations

12.

Morford, LaRonda L., Christopher Bowman, Diann Blanset, et al.. (2011). Preclinical safety evaluations supporting pediatric drug development with biopharmaceuticals: strategy, challenges, current practices. Birth Defects Research Part B Developmental and Reproductive Toxicology. 92(4). n/a–n/a. 16 indexed citations

13.

Younes, Anas, Julie M. Vose, Andrew D. Zelenetz, et al.. (2010). A Phase 1b/2 trial of mapatumumab in patients with relapsed/refractory non-Hodgkin's lymphoma. British Journal of Cancer. 103(12). 1783–1787. 112 indexed citations

14.

Plummer, Ruth, Gerhardt Attard, Simon Pacey, et al.. (2007). Phase 1 and Pharmacokinetic Study of Lexatumumab in Patients with Advanced Cancers. Clinical Cancer Research. 13(20). 6187–6194. 198 indexed citations

15.

Humphreys, Robin & Wendy Halpern. (2007). Trail Receptors: Targets for Cancer Therapy. Advances in experimental medicine and biology. 615. 127–158. 51 indexed citations

16.

Halpern, Wendy, Patrick B. Lappin, Thomas A. Zanardi, et al.. (2006). Chronic Administration of Belimumab, a BLyS Antagonist, Decreases Tissue and Peripheral Blood B-Lymphocyte Populations in Cynomolgus Monkeys: Pharmacokinetic, Pharmacodynamic, and Toxicologic Effects. Toxicological Sciences. 91(2). 586–599. 113 indexed citations

17.

Humphreys, Robin, Carol Poortman, K McCormick, et al.. (2005). HGS-TR2J, an agonistic, TRAIL receptor 2 monoclonal antibody, actively and rapidly stimulates the TRAIL receptor pathway that leads to significant inhibition of tumor growth in human tumor cell lines in vitro and in vivo. Cancer Research. 65. 1038–1038. 2 indexed citations

18.

Roach, Charlotte, Jon Askaa, Dennis E. Chenoweth, et al.. (2004). Development of sensitive and specific immunohistochemical assays for pro-apoptotic TRAIL-receptors. Cancer Research. 64. 1145–1145. 6 indexed citations

19.

Melder, Robert J., Blaire L. Osborn, Todd Riccobene, et al.. (2004). Pharmacokinetics and in vitro and in vivo anti-tumor response of an interleukin-2-human serum albumin fusion protein in mice. Cancer Immunology Immunotherapy. 54(6). 535–547. 92 indexed citations

20.

Halpern, Wendy, Todd Riccobene, Kevin C. Baker, et al.. (2002). AlbugraninTM, a Recombinant Human Granulocyte Colony Stimulating Factor (G-CSF) Genetically Fused to Recombinant Human Albumin Induces Prolonged Myelopoietic Effects in Mice and Monkeys. Pharmaceutical Research. 19(11). 1720–1729. 68 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact